Equities research analysts expect Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) to report ($1.08) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have provided estimates for Anthera Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.11) and the highest is ($1.06). Anthera Pharmaceuticals reported earnings of ($2.80) per share during the same quarter last year, which would suggest a positive year over year growth rate of 61.4%. The business is expected to report its next earnings results on Tuesday, August 8th.

On average, analysts expect that Anthera Pharmaceuticals will report full-year earnings of ($4.96) per share for the current financial year, with EPS estimates ranging from ($5.33) to ($4.53). For the next financial year, analysts forecast that the firm will post earnings of ($3.95) per share, with EPS estimates ranging from ($5.65) to ($2.86). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that cover Anthera Pharmaceuticals.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.47) by $0.56.

ANTH has been the subject of several research reports. Jefferies Group LLC restated a “hold” rating and issued a $2.25 price objective on shares of Anthera Pharmaceuticals in a report on Monday, May 15th. ValuEngine lowered shares of Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, Zacks Investment Research lowered shares of Anthera Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. Anthera Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $10.21.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its position in shares of Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares during the period. UBS Group AG raised its position in shares of Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares during the last quarter. Finally, Sabby Management LLC raised its position in shares of Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/07/24/1-08-earnings-per-share-expected-for-anthera-pharmaceuticals-inc-nasdaqanth-this-quarter.html.

Shares of Anthera Pharmaceuticals (ANTH) traded down 2.579% during trading on Monday, reaching $1.549. 120,858 shares of the company were exchanged. The stock has a 50-day moving average price of $1.66 and a 200-day moving average price of $1.06. The stock’s market capitalization is $15.61 million. Anthera Pharmaceuticals has a one year low of $1.47 and a one year high of $28.40.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get a free copy of the Zacks research report on Anthera Pharmaceuticals (ANTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.